Multiple myeloma Flashcards
Define multiple myeloma
• neoplastic clonal proliferation of plasma cells producing a monoclonal immunoglobulin
resulting in end organ dysfunction
• usually single clone of plasma cells, although biclonal myeloma also occurs. Rarely nonsecretory
Pathophysiology of Multiple myeloma
malignant plasma cells secrete monoclonal antibody
95% produce M protein (monoclonal Ig = identical heavy chain + identical light chain, or
light chains only)
- IgG 50%, IgA 20%, IgD 2%, IgM 0.5%
- 15-20% produce free light chains or light chains alone found in either:
– serum as an increase in the quantity of either kappa or lambda light chain (with an
abnormal kappa:lambda ratio)
– urine has Bence-Jones protein
Px & Cx of Multiple myeloma
• bone disease: pain (usually back), bony tenderness, pathologic fractures
- lytic lesions are classical (skull, spine, proximal long bones, ribs)
- increased bone resorption secondary to osteoclast activating factors such as PTHrP
• anemia: weakness, fatigue, pallor secondary to bone marrow suppression
• weight loss
• infections: usually S. pneumoniae and Gram-negatives, secondary to suppression of normal plasma cell function
• hypercalcemia: N/V, confusion, constipation, polyuria, polydipsia
- secondary to increased bone turnover
• renal disease/renal failure
most frequently causes cast nephropathy
• bleeding
- secondary to thrombocytopenia, may see petechiae, purpura
- can also be caused by acquired von Willebrand disease
How can you detect light chains in urine?
Need sulfosalicylic acid or 24 h urine protein for immunofixation or electrophoresis.
Routine urinalysis will not detect light chains as dipstick detects albumin
Light chain disease in multiple myeloma
- % of MM
- major problem
- prognosis factor
15% of MM produce only light chains.
Renal failure is a major problem.
Kappa > lambda light chain has better prognosis.
How do you diagnose multiple myeloma?
- serum or urinary monoclonal protein
- presence of clonal plasma cells in bone marrow or a plasmacytoma
- presence of end-organ damage related to plasma cell dyscrasia, such as:
- increased serum Ca2+
- lytic bone lesions
- anemia
- renal failure
Rx of multiple myeloma
- treatment is non-curative
- autologous stem cell transplant if 65 yr old or transplant-ineligible
• supportive management:
- bisphosphonates for those with osteopenia or lytic bone lesions (requires renal dosing)
- local XRT for bone pain, spinal cord compression
- kyphoplasty for vertebral fractures to improve pain relief and regain height
- treat complications: hydration for hypercalcemia and renal failure, bisphosphonates for
severe hypercalcemia, prophylactic antibiotics, erythropoietin for anemia, DVT prophylaxis
Median survival of multiple myeloma
median survival based on stage, usually 16-70 mo